Skip Navigation



JAC Advance Access published online on May 26, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh292
© 2004 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/1/6    most recent
dkh292v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Siliciano, J. D.
Right arrow Articles by Siliciano, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siliciano, J. D.
Right arrow Articles by Siliciano, R. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Leading article

A long-term latent reservoir for HIV-1: discovery and clinical implications

Janet D. Siliciano 1 Robert F. Siliciano 1*

1 Department of Medicine, Johns Hopkins University School of Medicine and Howard Hughes Medical Institute, Baltimore, MD 21205, USA

* To whom correspondence should be addressed. E-mail: rsiliciano{at}jhmi.edu.


  Abstract

Despite the remarkable success of highly active antiretroviral therapy (HAART) for the treatment of HIV-1 infection, it now appears that the infection is intrinsically incurable with antiretroviral therapy alone. The major reason is that the virus can persist in a latent form in resting memory CD4 cells. These cells arise when infected CD4+ lymphoblasts carrying an integrated copy of the HIV-1 genome revert back to a resting memory state. In this resting state, CD4 cells are minimally permissive for virus gene expression, and infected memory cells can survive for many years. Following re-exposure to the relevant antigen or other activating stimuli, these cells can begin to produce virus again. The existence of a stable reservoir has altered treatment strategies in several ways. HAART is no longer given with the goal of eradication. In addition, the reservoir serves as a permanent archive for wild-type virus and for drug-resistant variants that arise during treatment. Thus, once resistance to a particular drug arises, the patient will always carry that resistance. Interruption in treatment results in the re-emergence of the original wild-type virus, which often replicates better than drug-resistant virus. Although HAART cannot eradicate the infection, current regimens do come close to stopping virus evolution. Free viruses found in the plasma at low levels in patients on HAART resemble viruses in the latent reservoir and do not contain new drug resistance mutations. Thus although HAART cannot produce eradication, lifetime control of the infection with antiretroviral drugs may be possible.

Key Words: Keywords: latency, HIV, therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
T. L. Kieffer, A. D. Kwong, and G. R. Picchio
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
J. Antimicrob. Chemother., November 10, 2009; (2009) dkp388v1.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
T. L. Whiteside, P. Piazza, A. Reiter, J. Stanson, N. C. Connolly, C. R. Rinaldo Jr., and S. A. Riddler
Production of a Dendritic Cell-Based Vaccine Containing Inactivated Autologous Virus for Therapy of Patients with Chronic Human Immunodeficiency Virus Type 1 Infection
Clin. Vaccine Immunol., February 1, 2009; 16(2): 233 - 240.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. J. Hurwitz, G. Asif, N. M. Kivel, and R. F. Schinazi
Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65R Mutation Using a Population Pharmacokinetic and Enzyme Kinetic Simulation Model
Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4241 - 4250.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Marini, J. M. Harper, and F. Romerio
An In Vitro System to Model the Establishment and Reactivation of HIV-1 Latency
J. Immunol., December 1, 2008; 181(11): 7713 - 7720.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Palmer, F. Maldarelli, A. Wiegand, B. Bernstein, G. J. Hanna, S. C. Brun, D. J. Kempf, J. W. Mellors, J. M. Coffin, and M. S. King
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
PNAS, March 11, 2008; 105(10): 3879 - 3884.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Rollman, M. Z. Smith, A. G. Brooks, D. F. J. Purcell, B. Zuber, I. A. Ramshaw, and S. J. Kent
Killing Kinetics of Simian Immunodeficiency Virus-Specific CD8+ T Cells: Implications for HIV Vaccine Strategies
J. Immunol., October 1, 2007; 179(7): 4571 - 4579.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Nakata, M. Amano, Y. Koh, E. Kodama, G. Yang, C. M. Bailey, S. Kohgo, H. Hayakawa, M. Matsuoka, K. S. Anderson, et al.
Activity against Human Immunodeficiency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine
Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2701 - 2708.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Amano, Y. Koh, D. Das, J. Li, S. Leschenko, Y.-F. Wang, P. I. Boross, I. T. Weber, A. K. Ghosh, and H. Mitsuya
A Novel Bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI), GRL-98065, Is Potent against Multiple-PI-Resistant Human Immunodeficiency Virus In Vitro
Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2143 - 2155.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. Shen, H.-C. Yang, Y. Zhou, A. J. Chase, J. D. Boyer, H. Zhang, J. B. Margolick, M. C. Zink, J. E. Clements, and R. F. Siliciano
Novel Pathway for Induction of Latent Virus from Resting CD4+ T Cells in the Simian Immunodeficiency Virus/Macaque Model of Human Immunodeficiency Virus Type 1 Latency
J. Virol., February 15, 2007; 81(4): 1660 - 1670.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
B. Cervasi, M. Paiardini, S. Serafini, A. Fraternale, M. Menotta, J. Engram, B. Lawson, S. I. Staprans, G. Piedimonte, C. F. Perno, et al.
Administration of Fludarabine-Loaded Autologous Red Blood Cells in Simian Immunodeficiency Virus-Infected Sooty Mangabeys Depletes pSTAT-1-Expressing Macrophages and Delays the Rebound of Viremia after Suspension of Antiretroviral Therapy.
J. Virol., November 1, 2006; 80(21): 10335 - 10345.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. A. Frankel, B. Marchand, D. Turner, M. Gotte, and M. A. Wainberg
Impaired Rescue of Chain-Terminated DNA Synthesis Associated with the L74V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase
Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2657 - 2664.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. W. North, K. K. A. Van Rompay, J. Higgins, T. B. Matthews, D. A. Wadford, N. C. Pedersen, and R. F. Schinazi
Suppression of Virus Load by Highly Active Antiretroviral Therapy in Rhesus Macaques Infected with a Recombinant Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1
J. Virol., June 15, 2005; 79(12): 7349 - 7354.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.